It will compete with Eisai and Biogen's Leqembi, which the FDA approved last year ... Go deeper: Where the future of Alzheimer's drugs is heading Get more health news in your inbox with Axios ...

The Food and Drug Administration on ... Patients who carry two copies of the Alzheimer's risk gene, ApoE4, are more likely to ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

WASHINGTON--U.S. officials have approved another Alzheimer’s drug ... get the drugs and how long they might benefit. The new drug’s approval was expected after an outside panel of FDA ...

The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer's and ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

Eli Lilly received FDA breakthrough status for its donanemab Alzheimer's drug, speeding the agency's review of the product. The shares are higher. Eli Lilly (LLY) shares rose Thursday after ...